Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | RXRA | P19793 | 8/20 | 0.64 |
| ▸ | RXRB | P28702 | 7/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.59 |
| ▸ | RXRG | P48443 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.54 |
| ▸ | BAD | Q92934 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13757206 | 1.00 | MAPT (0.65) | MAPTSMN1; SMN2RXRARXRBEGFR | |
| SCHEMBL15960261 | 0.93 | SMN1; SMN2 (0.74) | MAPTSMN1; SMN2RXRARXRBHSD17B1 | |
| SCHEMBL1169167 | 0.93 | SMN1; SMN2 (0.74) | MAPTSMN1; SMN2RXRARXRBHSD17B1 | |
| SCHEMBL11754087 | 0.91 | HSD17B1 (0.70) | MAPTSMN1; SMN2RXRARXRBEGFR | |
| SCHEMBL23202431 | 0.89 | EGFR (0.72) | RXRARXRBEGFRRXRGHSD17B10 | |
| SCHEMBL21133280 | 0.89 | EGFR (0.72) | RXRARXRBEGFRRXRGHSD17B10 | |
| SCHEMBL142861 | 0.89 | EGFR (0.72) | RXRARXRBEGFRRXRGHSD17B10 | |
| SCHEMBL21133337 | 0.89 | EGFR (0.72) | RXRARXRBEGFRRXRGHSD17B10 | |
| SCHEMBL22734016 | 0.89 | EGFR (0.72) | RXRARXRBEGFRRXRGHSD17B10 | |
| SCHEMBL864660 | 0.89 | EGFR (0.72) | RXRARXRBEGFRRXRGHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170081345-A1 | METAL-ORGANIC FRAMEWORKS CHARACTERIZED BY HAVING A LARGE NUMBER OF ADSORPTION SITES PER UNIT VOLUME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-03-23 | — | — | US | disclosed |
| US-20170008915-A1 | ACID, SOLVENT, AND THERMAL RESISTANT METAL-ORGANIC FRAMEWORKS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081345-A1 | METAL-ORGANIC FRAMEWORKS CHARACTERIZED BY HAVING A LARGE NUMBER OF ADSORPTION SITES PER UNIT VOLUME | EPCAM, SOD1, ABCB7 | MAPT 1394/4885SMN1; SMN2 1497/4885RXRA 2286/4885 |
| US-20170008915-A1 | ACID, SOLVENT, AND THERMAL RESISTANT METAL-ORGANIC FRAMEWORKS | HAO2, ASF1A, FTO | MAPT 2232/4885SMN1; SMN2 1101/4885RXRA 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.